Connect with us

Headlines

Bausch + Lomb Gets FDA Approval for Glaucoma Drug

mm

Published

on

It was licensed from Nicox.

Bausch + Lomb and Nicox S.A., an international ophthalmic company, announced that the U.S. Food and Drug Administration has approved the New Drug Application for Vyzulta.

Vyzulta is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The drug (latanoprostene bunod ophthalmic solution, 0.024 percent) is described in a press release as being the first prostaglandin analog with one of its metabolites being nitric oxide.

“With today’s approval of VYZULTA, our customers and their patients with glaucoma now have a new treatment option that can help provide consistent and sustained IOP lowering, the only modifiable risk factor that can help slow down the progression of the disease,” said Joseph C. Papa, chairman and CEO of Valeant Pharmaceuticals International, parent company of Bausch + Lomb. “We expect to make this new advancement available for those who suffer with glaucoma before the end of the year.”

Lowering intraocular pressure, even in patients with normal baseline levels, can delay, or even prevent damage to optic nerves, helping to reduce the risk of glaucomatous visual field loss, the release explains.

Advertisement

Vyzulta was licensed on a global basis to Bausch + Lomb from Nicox. As a result of this approval, Nicox will receive $17.5 million from Bausch + Lomb and will make a $15 million payment to Pfizer under a previous license agreement.

SPONSORED VIDEO

Crizal® Sapphire™ HR: Invisible Shield of Protection

Your patients’ main concerns of anti-glare, scratch resistance, and easiness to clean are covered. Crizal Sapphire HR, the latest and most advanced product in the Crizal No-Glare range, is now widely available across lab networks and through all major managed vision care providers. Crizal Sapphire HR is available with Essilor’s advanced lens designs such as Varilux® progressive lenses and Eyezen® enhanced single vision lenses. Click here to learn more. *External laboratory tests and internal technical tests – 2020. Compared to the competitor most known lens-brands by consumers (2019 external brand tracking in 11 countries). The word ’overall’ refers to anti-reflective coatings important criteria, ranked through an external quantitative consumer study – 2019.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular